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Protein phosphatase 1CaWe developed a quantitative method to measure the activity of cyclin-dependent kinases (Cdks) by
western blotting, without radioisotopes. We prepared a recombinant protein substrate based upon
the natural Cdk1 substrate, PP1Ca. By combining this substrate in a western blot method using ﬂuo-
rochrome based antibodies and phospho-imager analysis, we measured the Km of ATP binding to
Cdk1 to be 3.5 lM. We then measured Cdk1 activity in cell extracts from interphase or mitotic cells,
and demonstrated that previously identiﬁed Cdk inhibitors could be detected by this assay. Our data
show that we have a safe, reliable assay to identify Cdk1 inhibitors and measure Cdk1 activity.
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The measure of cyclin dependent kinase (Cdk) activity is a con-
venient means to identify cell cycle phases by using a biochemical
approach. Cyclin dependent kinase 1 (Cdk1)/cyclin B1 complex is
the key enzyme that drives mitosis; its protein subunits and role
are conserved in eukaryotic species. It is a complex composed of
a catalytic subunit (Cdk1) and one regulatory subunit cyclin B1,
which is expressed in G2 and early M-phases of the cell cycle [1].
The activation of Cdk1/cyclin B1 complex is regulated by several
different steps. Initially, the Cdk1/cyclin B1 complex is held inac-
tive by phosphorylation of the ATP binding site. This permits the
production of the complex, prior to its activation at the G2/M-
phase transition through positive feedback mediated dephospho-
rylation. Exit from M-phase is coordinated by ubiquitin-dependent
degradation of cyclin B1 [2]. When active, Cdk1 phosphorylates
hundreds of different protein substrates [3], which results in
cellular events such as morphology change, chromosome conden-sation, nuclear envelope breakdown, and segregation of condensed
chromosomes. There are at least eleven other Cdk related proteins
in cells, some, such as cyclin dependent kinase 2 (Cdk2), have
phosphorylation activity that overlaps with that of Cdk1 [3]. Much
of our understanding about cell proliferation in health and disease
has been guided by measuring Cdk1 activity in cells.
Potential Cdk substrates can be identiﬁed by a canonical con-
sensus sequence that includes a serine or threonine N-terminal
to a proline with a basic amino acid such as a lysine or arginine
within a 3 to +3 relative to the phosphoacceptor amino acid
[4]. This sequence shares similarities to the phosphoacceptor se-
quences in substrates of the MAP kinase family, therefore biologi-
cal evidence is required to establish protein kinase–substrate
relationships. A Cdk consensus sequence is present in the human
protein phosphatase PP1Ca at T320 [5,6]. Cdk1/cyclin B1 is re-
ported to phosphorylate PP1Ca during mitosis, as demonstrated
by western blotting with antibodies that distinguish phospho-
T320 PP1Ca from non-phosphorylated T320 PP1Ca [7]. With the
knowledge of the Cdk phosphorylation consensus sequence and
by acquiring speciﬁc antibodies, it is possible to design speciﬁc as-
says to measure Cdk activity.
Current methods to measure Cdk1 activity in vitro use the his-
tone H1 assay. In this technique, cell extracts or puriﬁed Cdk1 are
combined with a buffer containing c[32P] ATP and incubated with
histone H1 [8]. Phosphorylated histone H1 is then resolved by
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solid support and counted by a detector. The amount of P32 incor-
porated onto histone H1 is a measure of the activity of Cdk1 [8].
Although this method is widely used, there is a growing problem
in handling radio-isotopes in research laboratories because of the
dangers of exposure to ionizing radiation, requirements for special-
ized training, and handling of radioactive waste. These drawbacks
motivated us to develop non-radioactive method of measuring
Cdk1 activity. Other methods to measure Cdk1 activity include
the use of a FRET biosensor that is composed of ﬂuorescently la-
beled Cdk1 protein substrate and its binding partner [9]. The FRET
system enables one to measure Cdk1 activity in live, individual
cells, rather than a cell extract, as described here.
We have previously reported that we could measure Cdk1
activity in human cells undergoing mitosis with damaged DNA, a
process known as checkpoint adaptation [10]. Since checkpoint
adaptation had not been described in camptothecin (CPT) treated
cells, a biochemical measure of Cdk1 in addition to morphological
changes such as cell rounding was required to conﬁrmmitosis [11].
In this paper, we describe the parameters of a method to measure
Cdk activity using a recombinant protein substrate based upon hu-
man PP1Ca sequence and speciﬁc antibodies. We demonstrate that
this assay is quantitative and that it can be used to detect Cdk
small molecule inhibitors or Cdk1 activity in extracts prepared
from human cells. We propose our assay as an alternative Cdk1 ki-
nase assay to avoid the inconveniences and dangers of handling
radio-isotopes.
2. Materials and methods
2.1. Cell culture
The human cell line HT-29 was obtained from the American
Type Culture Collection. HT-29 cells were maintained in RPMI
1640 (Life Technologies) medium supplemented with 10% decom-
plemented fetal calf serum (PAA Laboratories, Etobicoke, Ontario),
2 mM L-glutamine (Invitrogen). The human cell line MCF7 was a
gift from Dr. O. Kovalchuk. MCF7 cells were maintained in Ad-
vanced MEM (Life Technologies) media supplemented with 10%
decomplemented fetal calf serum and 2 mM L-glutamine (Invitro-
gen). Cells were grown at 37 C in 5% CO2 and media were changed
every second or third day. The compounds camptothecin (Sigma)
and nocodazole (Sigma) were used at concentrations of 25 nM
and 200 ng/mL, respectively.
2.2. Flow cytometry
Total cultures were collected by trypsinization. Cells were
washed in phosphate-buffered saline (PBS) and ﬁxed in 90% etha-
nol (20 C) for at least 24 h. For analysis, samples were incubated
for 20 min in wash buffer with 0.02 mg/mL propidium iodide
(Invitrogen) and 0.2 mg/mL RNAse A (Sigma), and analyzed by a
FACS Canto II ﬂow cytometer (BD Biosciences) using BD FACSDiva
software. Gating was set using control samples. Experiments were
repeated at least three times.
2.3. Extract preparation
Cells were resuspended in extraction buffer (50 mM 4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) pH 7.4,
50 mM NaF, 10 mM EGTA (ethyleneglycol-bis (beta-aminoethyle-
ther)- N,N0-tetraacetic acid), 50 mM b-glycerophosphate, 1 mM
ATP, 1 mM (DTT) dithiothreitol, 1% Triton X-100, 10 lg/mL
RNAse A, 0.4 U/mL DNAse I, with Roche protease inhibitors cock-
tail) at a concentration of 20,000 cells per lL, on ice for 30 min[12]. After ﬁve passages through a 26 g needle at 4 C, the sus-
pension was centrifuged at 10,000g for 10 min at 4 C. Extracts
were used either for electrophoresis after being boiled for 5 min
in presence of 2 SDS sample buffer for measurement of Cdk/cy-
clin activity.
2.4. Preparation of recombinant GST-PP1C-S
BL21 bacteria transformed with the pGEX-PP1Ca His plasmid
were grown on a LB ampicillin (LB + AMP) plate at 37 C. Single
colonies were selected after 24 h and inoculated with LB + AMP
liquid media. Tubes were placed on a shake tray for 2 h at 37 C.
When the culture was slightly turbid, it was transferred into
500 mL of LB + AMP liquid media. The optical density was
monitored and the expression was induced at OD600 = 0.6, with
0.4 mM (IPTG) isopropyl b-D-1-thiogalactopyranoside. Samples
were taken at set times until induction was stopped after 5 h.
Samples were combined with 2 SDS reducing buffer and
analyzed by SDS–PAGE. The remainder of the culture was centri-
fuged at 10,000g for 20 min, the supernatant was removed, and
the pellet was stored at 80 C. Bacteria were thawed and pellet
was re-suspended in lysis buffer (50 mM phosphate buffer pH
6.8, 1 mM EDTA, 100 mM NaCl, protease inhibitor (1/10 mL) at a
ratio of 1 mL per g. Lysozyme solution (50 mg/mL Sigma L7651
in 10 mM phosphate buffer (pH 6.8), 1 mM EDTA) was then added
at ratio of 50 lL/10 mL and incubated for 10 min. The extract was
sonicated at 50% for 10 min and then centrifuged at 10,000g. The
supernatant was removed and the pellet was re-suspended with
fresh lysis buffer and stored on ice. Recombinant GST-PP1C-S
was puriﬁed by glutathione afﬁnity chromatography using
glutathione coated beads. The extract was passed through the
column, which was washed three times with 10 mM phosphate
buffer. Elution buffer (10 mM reduced glutathione and 50 mM Tris
(pH 7.9)) was used to collect GST-PP1C-S. 100 lL samples of the
ﬂow through, phosphate buffer washes, and elutions were
collected and analyzed by SDS–PAGE. GST-PP1C-S was dialyzed
with 50 mM Tris (pH 7.9) for 6 h (ﬁnal volume 9.5 mL).
GST-PP1C-S was analyzed on a protein chip (On-Chip-Electropho-
resis; Agilent Technologies) with a Bioanalyzer 2100 and esti-
mated to be greater than 95% pure. GST-PP1C-S was stored at
80 C until use.
2.5. Cdk1 kinase assay
Cdk1 phosphorylation reactions (20 lL total volume) were as
follows: 10 lL of 2 Cdk1 phospho assay buffer (50 mM b-glycer-
ophosphate pH 7.4, 10 mM MgCl2, 10 mM NaF, 1 mM DDT) with
200 lM ATP (or as needed) and 5 lL of either 80 ng/lL GST or
GST-PP1C-S. Reactions were initiated by adding either 5 lL of
Cdk1/cyclin B1 (Millipore, 14–450) at a concentration of 8.6 ng/
lL unless otherwise stated, Cdk2/cyclin A (Millipore, 14–448) as
indicated or 5 lL of whole cell extracts diluted in lysis buffer
(50 mM HEPES, pH 7.4; 1% Triton X-100; 50 mM NaF; 50 mM
b-glycerophosphate; 10 mM EGTA; 1 mM ATP; DNase 1; 10 lg/
mL RNase A; and 1 mM DDT) to 100 cells/lL. Final reactions
contained 400 ng of either GST or GST-PP1C-S, and either
43.2 ng of Cdk1/cyclin B1 or an extract of the equivalent of
500 cells in a 20 lL volume. Reactions were incubated for
15 min at 30 C. Reactions were stopped by adding an equal
volume of 2 SDS sample buffer and heating to 95 C for 5 min.
All kinase reactions were performed at least three times. All
compounds including those used in assays in vitro, CR8, and mer-
iolins (ManRos Therapeutics, Roscoff, France), were dissolved in
dimethyl sulfoxide (DMSO) to a concentration of 10 mM and
stored at 20 C until use.
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Reaction mixtures were separated in duplicate on a 12% SDS gel
with a 4% stacking gel at 200 volts. Proteins were transferred to
nitrocellulose with a semi-dry electroblotter system (BioRad) for
30 min at 25 volts. Subsequently, the membrane was blocked with
either 5% low fat milk in Tris buffered saline TBS-0.1% Tween-20
(TBST) or 2% BSA in TBS-0.1% Tween-20 (TBS-T), and incubated
overnight with the indicated primary antibody as follows: anti-
phospho-PP1 alpha (Thr320) monoclonal antibody (Ab62334, Ab-
cam, 1:300,000), or anti-phospho-PP1 alpha (Thr320) polyclonal
antibody (2581S, Cell Signalling polyclonal, 1:1000) or anti-GST
(G7781, Sigma–Aldrich, 1:20,000). After washing, the membrane
was incubated with Alexa Fluor 488-coupled anti-mouse or anti-
rabbit antibodies (A11059, A11008, Invitrogen, 1:400) or alkaline
phosphatase conjugated anti-rabbit antibody (AP132A, Millipore,
1:2500). Western blots were performed at least three times.
2.7. Data analysis
Membranes were scanned with a Typhoon Trio Imager (Emis-
sion Filter: 526SP; Excitation: Blue 488; Voltage: 450–480 volts).
Signals were analyzed using ImageQuant software. Lanes were
manually drawn and the signal area was selected. A background
section of similar dimensions to the signal detection box was then
manually drawn and subtracted. The signal volume in positive pix-
els was determined based on a medium scan of 100 microns. Each
signal was measured at least twice and the mean signal volume in
ﬂuorescent units was plotted using Excel software. Signals gener-
ated from GST membranes were used to standardize GST-PP1C-S
signals. ATP-Km values were calculated from three independent
experiments using the Lineweaver–Burk method and analyzed
with Excel software to determine a best ﬁt curve.
3. Results
The phosphorylation of human protein phosphatase 1Ca (PP1-
Ca) on threonine 320 (T320) by Cdk1 has been previously
described [7]. To conﬁrm that this event occurs in other human
cells, we cultivated the human cell colon carcinoma cell lineA
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Fig. 1. Protein phosphatase 1Ca is phosphorylated on T320 during mitosis. (A) Human
25 nM CPT for 24 h (middle panel) or treated with nocodazole for 24 h (bottom panel). D
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markers in kDa are shown on the left.HT-29 and tested it for the presence of phosphorylated T320 by
western blotting. Cells were either not-treated, treated with
25 nM camptothecin, or with 200 ng/mL nocodazole, and analyzed
at 24 h by ﬂow cytometry to measure DNA content (Fig. 1A). As ex-
pected, the not-treated cells were predominantly in G1 with a G2/
M-phase fraction, whereas the camptothecin treated cells were
predominantly in S-phase and G2, and the nocodazole treated cells
were in mitosis. We prepared extracts from these cultures and ana-
lyzed them by western blotting with anti-phosphoT320 PP1-Ca, or
anti-phosphoY15 Cdk1, or anti-actin antibodies. The anti-phosp-
hoT320 PP1-Ca signal was strongest in extracts prepared from
nocodazole treated cells, which contained the mitotic cells
(Fig. 1B). This sample contained the weakest anti-phosphoY15
Cdk1 signal, conﬁrming that the cells were in mitosis. By contrast
the camptothecin treated cells had a strong anti-phosphoY15 Cdk1
signal. The anti-actin western blot conﬁrmed that equal amounts
of protein were present in each extract. These data conﬁrmed that
the phospho-T320 PP1-Ca antibodies detect phosphoT320 PP1-Ca
in HT-29 cell extracts prepared at the time when Cdk1 is active.
We recovered the human sequence of PP1-Ca from public data
bases (Supplementary Fig. S1) and designed cDNA sequences
encoding amino acids 316–324 that ﬂanked the phosphosite
T320 (Fig. 2A). We also incorporated six histidines to the C-termi-
nus of the recombinant protein as a second epitope for anti-histi-
dine antibodies. These sequences were subcloned into a pGEX
plasmid to encode GST with a C-terminus that has the nine amino
acids from PP1-Ca followed by six histidines. The recombinant
protein, named GST-PP1C-S (S for substrate), is composed of 242
amino acids with a molecular weight of 28.5 kD (Fig. 2A).
We produced the recombinant protein in Escherichia coli that
harboured the plasmid pGEX-GST-PP1C-S and puriﬁed GST-PP1C-
S or GST proteins by glutathione bead afﬁnity chromatography
(Supplementary Fig. S1). We compared GST-PP1C-S, GST or pro-
teins from total human cell extracts by western blot analysis with
anti-GST antibodies, or anti-6 histidine antibodies or anti-pT320
PP1-Ca antibodies (Fig. 2B). The GST-PP1C-S was recognized by
the GST and 6 histidine antibodies (Fig. 2B, Lanes 3 and 4). In its
non-phosphorylated form as puriﬁed from E. coli, it was not recog-
nized by anti-pT320 PP1-Ca antibodies, although phosphorylated
PP1-Ca from a mitotic cell extract was recognized. These data1 2 3
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Fig. 3. Phosphorylation of GST-PP1C-S by Cdk1 and Cdk2. (A) GST (lanes 2, 3) or
GST-PP1C-S (lanes 4, 5) were either incubated in kinase buffer (lanes 2, 4) or kinase
buffer and Cdk1/cyclin B1 (lanes 3, 5). A total cell extract from nocodazole treated
HT-29 cells was prepared in parallel (lane 1). Samples were analyzed by western
blotting and developed with an anti-GST antibody. Positions of molecular weight
markers in kDa are shown on the left. (B) Samples, as described in A, were analyzed
by western blotting and developed with an anti-pT320 PP1-Ca antibody. (C) Equal
units of Cdk1/cyclin B1 or Cdk2/cyclin A were incubated with GST-PP1C-S (Lanes 1
and 5, 0 mU; lanes 2 and 6, 5 mU; lanes 3 and 7, 14 mU; lanes 4 and 8, 40 mU).
Samples containing 100 ng of substrate were analyzed by western blotting and
developed with anti-GST or anti-pT320 PP1Ca antibodies. The signal volumes were
measured by phospho-imager analysis and are shown below each lane.
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its native state, it did not interact with the anti-T320 PP1-Ca
antibody.
We then tested if recombinant GST-PP1C-S could be phosphor-
ylated by Cdk1, so that it would be recognized by anti-pT320PP1-Ca antibodies. Puriﬁed GST-PP1C-S was incubated with puri-
ﬁed Cdk1 in a protein kinase buffer that contained ATP (Fig. 3).
In control tests, the same procedure was followed but without
ATP. The reactions were stopped by the addition of SDS-sample
buffer and analyzed by western blotting with either anti-GST anti-
bodies or with anti-pT320 PP1-Ca antibodies. GST and GST-PP1C-S
were detected by an anti-GST western blot (Fig. 3A). By contrast,
GST-PP1C-S was readily detected by the anti-pT320 PP1-Ca anti-
bodies when GST-PP1C-S was incubated with Cdk1 (Fig. 3B lane
5), whereas GST protein was not detected. The only phosphate
acceptor amino acid that is present in GST-PP1C-S and not present
in GST, is threonine 232 (Fig. 2A). When GST-PP1C-S is not phos-
phorylated by Cdk1, it is not readily detected by the anti-phosp-
hoT320 PP1Ca antibody (Supplementary Fig. S2A). We then
compared GST-PP1C-S phosphorylation by similar units of Cdk1/
cyclin B1 or Cdk2/cyclin A, and found that these closely related ki-
nases phosphorylated the substrate to similar levels (Fig. 3C). We
noted, however, that the speciﬁc activity of Cdk2 in these experi-
ments was ﬁve times lower than that of Cdk1, therefore, to achieve
similar levels of GST-PP1C-S phosphorylation, we used ﬁve times
more Cdk2/cyclin A protein. These data demonstrate that GST-
PP1C-S can be phosphorylated by the two major Cdk family
members.
To explore the kinetic parameters of GST-PP1C-S phosphoryla-
tion by Cdk1, we varied the concentration of ATP while maintaining
protein substrate concentration (Supplementary Fig. S3). We found
that 50 lM of ATP was within the saturation region of the reaction
kinetics, a value that we use in standard assay conditions. Michalis–
Menton analysis of the signal volumes from western blotting of
GST-PP1C-S phosphorylation revealed a Km for ATP to be 3.5 lM
(N = 3). These data suggested that the western blot detection sys-
tem could be used to measure Cdk1 activity quantitatively.
With a robust assay to measure Cdk activity in vitro, we then
asked if the western blot method could be used to detect known
small molecule Cdk inhibitors. We set up the assay under standard
conditions, although we reduced the ATP concentration to 3 lM,
which is at Km. Prior to starting the assay we added either meriolin,
a potent Cdk inhibitor, at three different concentrations or we
added methyl-meriolin, an inactive analogue from the same chem-
ical family [13]. Meriolin strongly inhibited Cdk1 at 10 and 1 lM
concentrations, as previously reported, but now detected by the
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the phosphorylation of GST-PP1C-S by Cdk1. In related experi-
ments, we found that other Cdk inhibitors, including CR8 [14] or
meriolin active analogues, inhibited GST-PP1C-S phosphorylation
(Supplementary Fig. S2B). These data conﬁrmed that the western
blot assay can be used to detect or to verify the activity of Cdk1
inhibitors.
Knowing that we could reliably and quantitatively detect Cdk1
activity in vitro, we tested if we could detect Cdk1 activity present
in total extracts of human cancer cells. To obtain mitotic cell ex-
tracts, HT-29 cells were ﬁrst treated with nocodazole as described
in Fig. 1. Non-treated cells were treated with the equivalent
amount of the solvent DMSO. Extracts were prepared, incubated
with either GST or with GST-PP1C-S, and analyzed by western blot-
ting. In parallel, the assay was performed using only extraction
buffer. The GST only substrate did not produce any signals by blot-
ting with the anti-pT320-PP1-Ca antibody (Fig. 4B). By contrast, arelatively strong signal was detected when the GST-PP1C-S
substrate was incubated with mitotic extracts. The signal was
approximately 10 times more intense than that of non-treated cell
extracts and 40 times more intense than a buffer only (back-
ground) signal.
Although we demonstrated that GST-PP1C-S is phosphorylated
by Cdk1 and in cells extracts when Cdk1 is active, it remained
possible that the TP motif might be phosphorylated by the Erk1/
2 kinases, which also recognize TP or SP amino acids. To test this,
we prepared extracts from MCF7 cells treated with etoposide, a
topoisomerase II inhibitor that induces Erk1/2 activation [15]
(Fig. 5A). Despite the increase in Erk1/2 activation, we did not de-
tect GST-PP1C-S phosphorylation when comparing not-treated and
etoposide treated extracts. By contrast, HT-29 cells did not demon-
strate Erk1/2 activation when treated with nocodazole to produce
mitotic cells, (Fig. 5A). Under the conditions used here, only the
mitotic sample displayed GST-PP1C-S activity in HT-29 cells, even
though similar levels of Erk1/2 phosphorylation were present in
the not-treated and mitotic cells. These data support the conclu-
sion that the assay can be used to measure Cdk activity from
extracts prepared from cells in interphase or in mitosis.
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We developed a new recombinant protein substrate and
adapted the technique of western blotting to measure Cdk1 activ-
ity quantitatively in biochemical assays and cell extracts. In
designing a Cdk1/cyclin B1 substrate, we looked for one that was
phosphorylated uniquely in mitosis. We used the human enzyme
PP1-Ca as described by Kwon et al., which is phosphorylated on
T320 by Cdk1 during mitosis [7]. We validated these results prior
to launching a new Cdk1 assay (Fig. 1). We then prepared bacterial
expression plasmids using GST and 6-histidine tag sequences
in-frame with the published a nine amino acid sequence that con-
tained the PP1-Ca phosphorylation site. The GST tag has three roles
in this assay: it is used to puriﬁcation the substrate, to quantify
signal strength in assays, and it makes the recombinant substrate
large enough so that phosphorylation can be evaluated by SDS–
PAGE. We routinely include a 6 histidine sequence on the C-ter-
mini of recombinant proteins to aid in puriﬁcation, if required,
and to provide a convenient epitope to conﬁrm an intact C-termi-
nus (Fig. 2).
We tested two p-T320 PP1-Ca antibodies against GST-PP1C-S
and GST to ﬁnd the antibody and substrate concentrations under
which they were unlikely to interact with each other (Supplemen-
tary Fig. S4). For convenience, we chose to work with a monoclo-
nal antibody, which ensures that the antibody-substrate
interaction does not change after stock renewal. We based our
choice of secondary antibody upon excitation/emission spectra
available with our model of the phospho-imager, and upon signal
strength of several different types of ﬂuorochromes available
within those detection limits. Detailed analyses of ﬂuorochromes
and detection have been described elsewhere [16]; we found
empirically that the Alexaﬂuor 488 provided a robust intense sig-
nal that contributed to a 20-fold linear range of detection (data
not shown).
A phospho-imager detection system is ideal because of its ease
of use, rapid detection times and capacity to collect signals over a
large range of intensities. We compared signal strength of phos-
phorylated GST-PP1C-S acquired from a range of ATP concentra-
tions. The data were analyzed by the Michalis–Menton method
and a Km of 3.5 lM was calculated, which was lower that the Km
identiﬁed when using histone H1 substrates [17]. To calibrate sig-
nals between experiments we would suggest including known
phosphorylated GST-PP1C-S samples on successive SDS polyacryl-
amide gels. We would only compare signals from within the same
western blot analysis. For our standard assays, we routinely used
100 lM ATP substrate, which is approximately 30 times above
the Km and within the saturation region of the signal volume (Sup-
plementary Fig. S3).
In assays to detect Cdk inhibitors, we used the ATP-Km concen-
tration 3 lM ATP, a common practise in protein kinase inhibition
assays [18]. Inhibition of Cdk1 by meriolin (IC50 0.01 uM) [19] or
CR8 (IC50 0.4 uM) [14] were readily detected, whereas the inactive,
methylated form of meriolin, did not inhibit Cdk1. Although other
methods, including those using radiolabeled substrates are likely
more suitable for routine or high-throughput screening [20], the
western blot method is convenient for periodic analysis of a small
number of inhibitors.
The substrate can be recognized by Cdk2/cyclin A and Cdk1/cy-
clin B in tests in vitro. In cell based assays, we set the conditions to
detect mitotic Cdk1 activity, which likely do not detect other Cdks,
including Cdk2 complexes. These conditions have been previously
used to detect Cdk1 in cell extracts by histone H1 kinase assays
[12]. We excluded the possibility that we were measuring Erk1/2
kinase, which have some substrate overlap with Cdks. Under
conditions of Erk1/2 activation, we were not able to detectphosphorylation of the substrate. We had previously reported that
Cdk1 activity was high in cells that had undergone checkpoint
adaptation [10]. Here, we provide experimental detail to validate
the method and demonstrate that the assay detects Cdk1 activity
in mitotic cells and that this activity is approximately 10-fold high-
er than that of an exponentially growing, not-treated culture
(Fig. 4), as has been previously reported by other methods [12].
To maintain signals within the linear range of the assay, we found
that we could dilute extracts to an equivalent of 500 cells, suggest-
ing that the detection system is sensitive and can be applied to
most standard culture conditions. The ease of preparing the sub-
strate and the availability of a monoclonal antibody make this as-
say suitable for either routine or periodic use by a commonmethod
of western blotting.
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